AbCellera partners with RQ Bio on infectious disease treatments
Dr_Microbe/iStock via Getty Images
- AbCellera Biologics (NASDAQ:ABCL) will work with RQ Bio to identify optimal clinical candidates for up to three infectious disease targets chosen by the latter.
- The disease areas will include influenza and cytomegalovirus (CMV).
- Terms call for privately held RQ Bio to develop and commercialize antibodies resulting from the partnership. AbCellera (ABCL) will receive research payments and is eligible to receive milestone payments and royalties on net sales of products developed as part of the collaboration.
- Read why Seeking Alpha contributor Confoundedinterest reiterated their strong buy rating.